GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lepu Biopharma Co Ltd (HKSE:02157) » Definitions » Common Stock

Lepu Biopharma Co (HKSE:02157) Common Stock : HK$1,841.6 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Lepu Biopharma Co Common Stock?

Lepu Biopharma Co's quarterly common stock declined from Jun. 2023 (HK$1,815.1 Mil) to Dec. 2023 (HK$1,815.1 Mil) but then increased from Dec. 2023 (HK$1,815.1 Mil) to Jun. 2024 (HK$1,841.6 Mil).

Lepu Biopharma Co's annual common stock declined from Dec. 2021 (HK$1,875.5 Mil) to Dec. 2022 (HK$1,853.1 Mil) and declined from Dec. 2022 (HK$1,853.1 Mil) to Dec. 2023 (HK$1,815.1 Mil).


Lepu Biopharma Co Common Stock Historical Data

The historical data trend for Lepu Biopharma Co's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lepu Biopharma Co Common Stock Chart

Lepu Biopharma Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial 1,769.49 1,875.48 1,853.13 1,815.07 1,826.38

Lepu Biopharma Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,853.13 1,815.07 1,815.07 1,841.55 1,826.38

Lepu Biopharma Co Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Lepu Biopharma Co Business Description

Traded in Other Exchanges
N/A
Address
No. 651, Lianheng Road, Minhang District, Shanghai, CHN, 201612
Lepu Biopharma Co Ltd is a biopharmaceutical company focusing on oncology therapeutics and has one operating segment. The Group is principally engaged in the sales of pharmaceutical products and the research and development of new drugs. The majority operating entity of the Group is domiciled in the PRC. The company has established an integrated end-to-end platform across drug discovery, clinical development, CMC, and GMP-compliant manufacturing, encompassing all critical functions of the biopharmaceutical value chain.
Executives
Pu Zhongjie 2201 Interest of corporation controlled by you
Hu Chaohong 2201 Interest of corporation controlled by you
Pu Jue 2201 Interest of corporation controlled by you
Hao Chunmei 2202 Interest of your spouse
Su Rongyu 2101 Beneficial owner
Miracogen Inc. 2201 Interest of corporation controlled by you
Miracogen Limited 2101 Beneficial owner
Cereblue Limited 2201 Interest of corporation controlled by you
Bei Jing Hou De Yi Min Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Hou De Yi Min Xin Xi Ke Ji You Xian Gong Si 2101 Beneficial owner
Le Pu Bei Jing Yi Liao Qi Xie Gu Fen You Xian Gong Si 2101 Beneficial owner
Lv Yuan Shang Hai Ke Ji You Xian Gong Si 2101 Beneficial owner

Lepu Biopharma Co Headlines

No Headlines